Indication
Microcystic Adnexal Carcinoma
1 clinical trial
1 product
1 drug
Clinical trial
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Drug
T-VECProduct
Talimogene Laherparepvec